CDT EQUITY INC.
CDT Equity Inc. (CDT)
Overview
CDT Equity Inc., formerly known as Conduit Pharmaceuticals Inc., is a Naples, Florida-headquartered, Nasdaq-listed clinical-stage biopharmaceutical company (ticker CDT) that rebranded in 2026 alongside a broader strategic pivot. The stock is a deeply speculative micro-cap: as of mid-September 2026 it traded around $0.19 per share with a market capitalization of roughly $2.75 million, and the company's fiscal 2025 10-K explicitly discloses "substantial doubt regarding our ability to continue as a going concern." James Bligh, a co-founder of the original Conduit Pharmaceuticals, was recently reinstalled as CEO to lead what the company describes as its next phase of growth, and the filing shows only about 4.86 million shares outstanding, reflecting a history of reverse splits and dilution typical of distressed small-cap biotechs.
What They Do & How They Make Money
CDT Equity does not currently generate meaningful commercial revenue; instead, it pursues a capital-light drug-development strategy built around acquiring and advancing clinical-stage compounds that larger pharmaceutical companies have deprioritized but which already carry Phase 1 safety data — reducing the cost and risk of early-stage development. Its pipeline consists of three compounds licensed from AstraZeneca: AZD1656 and AZD5658, glucokinase activators being explored for autoimmune and inflammatory conditions, and AZD5904, a myeloperoxidase inhibitor being studied for idiopathic male infertility. Rather than funding these assets through expensive late-stage trials itself, CDT's stated strategy is to use solid-form chemistry (cocrystals and salts that can extend a compound's patent life by up to twenty years) and AI-assisted analysis — through a partnership with Sarborg Limited for disease mapping and signature analysis — to identify new therapeutic applications, then exit through licensing deals with larger pharmaceutical partners once assets reach a Phase 2-ready state. The company has also struck a joint-development agreement with Manoira Corporation to evaluate its pipeline for veterinary applications, uses Charles River Laboratories for preclinical testing, and has recently layered in unrelated diversification moves, including a SAFE note investment in peptide-market startup Pep'd Inc. and an increased stake in Sarborg tied to quantum-computing and cryptocurrency-forecasting applications — none of which currently produce revenue.
Competitors
CDT operates, in its own words, "in the highly competitive pharmaceutical and biotechnology industry" against numerous public and private drug developers, universities, and government research agencies, without naming specific direct competitors in its 10-K.
Competitive Position
CDT Equity has essentially no near-term competitive moat. It has no approved or commercially marketed products, no meaningful revenue, and an explicit going-concern qualification from its auditors — the single most important fact about the company's position today. Its only real assets are licensed rights to three previously deprioritized AstraZeneca compounds and a solid-form patent strategy that could, if successful, extend intellectual-property life on any eventual product; both are speculative and unproven. The strategic pivot toward AI-assisted drug repurposing, veterinary licensing, and now unrelated ventures like a peptide-market SAFE note and cryptocurrency-related investments reads more as a distressed company searching for a viable business model than as a company executing from strength, and recent Nasdaq listing-deficiency notices (since resolved) underscore the fragility of its public-company status. Until CDT Equity secures a licensing deal, meaningful financing, or clear clinical progress on one of its three legacy compounds, it remains a high-risk, pre-revenue shell-adjacent biotech rather than a business with any durable competitive advantage.